Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.38 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 5/20 | 0.37 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | BCR | P11274 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14949198 | 0.92 | KDR (0.39) | KMT2AKCNK3KCNK9KDRCDK5 | |
| SCHEMBL14949365 | 0.90 | ABL1 (0.37) | KMT2AKDRFLT1ABL1BCR | |
| SCHEMBL14949358 | 0.88 | KDR (0.38) | KMT2AKDRABL1MEN1MAPT | |
| SCHEMBL14949311 | 0.88 | CDK8 (0.40) | KDRFLT1ABL1BCREGFR | |
| SCHEMBL12336537 | 0.88 | BRAF (0.46) | KDRGSK3BABL1SYKMAPT | |
| SCHEMBL14949317 | 0.87 | KMT2A (0.40) | KMT2AKDRFLT1ABL1BCR | |
| SCHEMBL14949339 | 0.86 | SYK (0.38) | KMT2AKDRCCNB2CDK1CCNB1 | |
| SCHEMBL14949322 | 0.85 | ABL1 (0.38) | KMT2AKDRCCNB2CDK1CCNB1 | |
| SCHEMBL14949309 | 0.83 | ROCK1 (0.40) | KMT2AKDRFLT1ABL1BCR | |
| SCHEMBL14949337 | 0.82 | ABL1 (0.35) | KMT2AKDRFLT1ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160096824-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9212151-B2 | Heterocyclic compounds useful for kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150158828-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-8957216-B2 | Heterocyclic compounds useful for kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS INC (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | MAP4K2, MAP3K20, MAP3K19 | KMT2A 900/4885KCNK3 625/4885KCNK9 750/4885 |
| US-20150158828-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | MAP4K2, MAP3K20, MAP3K19 | KMT2A 900/4885KCNK3 625/4885KCNK9 750/4885 |
| US-20160096824-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | MAP4K2, MAP3K20, MAP3K19 | KMT2A 900/4885KCNK3 625/4885KCNK9 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.